GNPX - Genprex Inc

https://www.genprex.com

Momentum: Bearish

Recent News

Genprex Provides Update on Diabetes Gene Therapy Program - Genprex ( NASDAQ:GNPX )

Benzinga • 6 months, 4 weeks ago • score: 0.21

Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.

52W High

$3.97

52W Low

$0.14

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.64

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.27

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.18

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

5.52

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.33%

Institutions (25–75% balanced)

2.23%

Shares Outstanding

33,466,800

Float

33,361,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

0.85

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-6.12%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0131

0.0047

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025